Dr. Anula Jayasuriya
Anula Jayasuriya, MD, PhD, MBA
Founder & Managing Director, EXXclaim Capital; Co-founder EILSF, Los Altos Hills, California, USA
Anula Jayasuriya is a successful private equity executive and venture capitalist whose background combines deep business, scientific and medical knowledge with broad clinical, industry, entrepreneurial, and investment experience.
In 2013, Anula founded EXXclaim Capital, an early stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women’s Health. EXXclaim has to date made eight investments, including Wildflower Health (www.wildflowerhealth.com), Sandstone Diagnostics (trakfertility.com), Softhealth (www.softhealthtech.com), Naia Health (naiamom.com) and nVision Medical. nVision Medical’s acquisition in April, 2018 by Boston Scientific Inc. for $275 Million (news.bostonscientific.com) has brought fresh validation to EXXClaim’s investment focus and the significant business opportunity in women’s health.
In 2006 Anula co-founded the “Evolvence India Life Science Fund” (www.invascent.com), the very first fund in India to focus exclusively on health care and invest in Indian pharmaceutical, biotechnology, medical device and contract services companies. EILSF has garnered seven successful exits to date, including Health Care Global (HCG www.healthcareglobal.com), the largest cancer care network in India, sourced and managed by Anula. EILSF’s stake in HCG was acquired by Temasek in 2013. Anula was a partner in the successor fund, “India Life Science II”, where she led investments in Oliva Dermatology (www.olivaclinic.com) and Oasis Fertility (oasisindia.in), until she left in 2017 to focus on US investments.
Anula was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP Business Development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation.
Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Anula also holds a M. Phil. in pharmacology from the University of Cambridge, in England.
Anula sits on the boards of Ocimum BioSolutions, and MapMyGenome, and served on the boards of Olvia Clinics and Oasis Infertility, all in Hyderabad, India. She was previously board chair of nVsion, San Francisco, and board member of Health Care Global (Bangalore), Lipomics (Sacramento) which was acquired by Tethys and Triesta BioSciences(Bangalore) which was acquired by Health Care Global.
She also serves on several non-profit boards, including The Harvard Business School Health Care Initiative Advisory Board, Astia, The Gruter Institute for Law and Behavioral Research, and LumindRDS.